Harmony Biosciences Holdings, Inc. (HRMY)

Market Cap	1.79B
Revenue (ttm)	617.51M
Net Income (ttm)	137.70M
Shares Out	56.79M
EPS (ttm)	2.31
PE Ratio	13.67
Forward PE	9.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	535,375
Open	31.79
Previous Close	31.69
Day's Range	31.17 - 32.37
52-Week Range	18.61 - 39.27
Beta	0.73
Analysts	Buy
Price Target	44.00 (+39.37%)
Earnings Date	Apr 30, 2024

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Har...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 246
• Stock Exchange: NASDAQ
• Ticker Symbol: HRMY

Financial Performance

In 2023, HRMY's revenue was $582.02 million, an increase of 32.93% compared to the previous year's $437.86 million. Earnings were $128.85 million, a decrease of -28.99%.

Analyst Forecast

According to 9 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is $44.0, which is an increase of 39.37% from the latest price.

Price Target

$44.0

(39.37% upside)

Analyst Consensus: Buy